---
created: '2026-02-13T17:51:33.078606Z'
description: The hypothesis that amyloid-beta accumulation is the primary initiating
  event in Alzheimer's disease, triggering downstream tau pathology, neuroinflammation,
  synaptic dysfunction, and neuronal death.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/pathway/amyloid-cascade/
slug: amyloid-cascade
tags:
- pathway
- neurodegeneration
- alzheimers
- amyloid-beta
- hypothesis
templateEngineOverride: njk
title: Amyloid Cascade
type: pathway
updated: '2026-02-13T17:51:33.078606Z'
---

{% raw %}
<h1>Amyloid Cascade</h1>
<h2>Overview</h2>
<p>The Amyloid Cascade Hypothesis, proposed by Hardy and Higgins in 1992, posits that the accumulation of amyloid-beta (Aβ) peptides is the initiating event in Alzheimer's disease pathogenesis. According to this model, Aβ deposition triggers a cascade of events including tau hyperphosphorylation, neuroinflammation, oxidative stress, synaptic dysfunction, and ultimately neuronal death. While central to AD research, the hypothesis has evolved and been debated.</p>
<h2>Amyloid-Beta Production</h2>
<h3>APP Processing</h3>
<pre><code>APP (Amyloid Precursor Protein)
          ↓
    ┌─────┴─────┐
    ↓           ↓
Non-amyloidogenic   Amyloidogenic
(α-secretase)       (β-secretase/BACE1)
    ↓                    ↓
  sAPPα              sAPPβ + C99
(neuroprotective)        ↓
                   (γ-secretase)
                        ↓
                  Aβ40 or Aβ42
</code></pre>
<h3>Key Peptides</h3>
<ul>
<li><strong>Aβ40</strong>: Most abundant (90%); less aggregation-prone</li>
<li><strong>Aβ42</strong>: Minor (10%); highly aggregation-prone; most toxic</li>
<li>Aβ42/40 ratio indicates pathology</li>
</ul>
<h2>Cascade Steps</h2>
<h3>1. Aβ Accumulation</h3>
<ul>
<li>Overproduction (genetic mutations)</li>
<li>Decreased clearance (APOE4, aging)</li>
<li>Imbalanced Aβ42/40 ratio</li>
</ul>
<h3>2. Oligomerization</h3>
<ul>
<li>Soluble Aβ oligomers form</li>
<li><strong>Most toxic species</strong></li>
<li>Synaptic dysfunction</li>
<li>LTP inhibition</li>
</ul>
<h3>3. Plaque Formation</h3>
<ul>
<li>Oligomers → protofibrils → fibrils</li>
<li>Extracellular amyloid plaques</li>
<li>Neuritic plaques with dystrophic neurites</li>
</ul>
<h3>4. Microglial Activation</h3>
<ul>
<li>Plaques trigger neuroinflammation</li>
<li>Pro-inflammatory cytokines</li>
<li>Chronic inflammation</li>
</ul>
<h3>5. Tau Pathology</h3>
<ul>
<li>Aβ triggers tau hyperphosphorylation</li>
<li>Neurofibrillary tangles form</li>
<li>Axonal transport disruption</li>
</ul>
<h3>6. Synaptic Failure</h3>
<ul>
<li>Synapse loss correlates with dementia</li>
<li>Cholinergic deficit</li>
<li>Glutamate dysregulation</li>
</ul>
<h3>7. Neuronal Death</h3>
<ul>
<li>Apoptosis and necrosis</li>
<li>Brain atrophy</li>
<li>Clinical dementia</li>
</ul>
<h2>Evidence Supporting</h2>
<h3>Genetic</h3>
<ul>
<li>APP mutations cause familial AD</li>
<li>PSEN1/PSEN2 mutations increase Aβ42</li>
<li>Down syndrome (3 copies APP) → early AD</li>
<li>APOE4 reduces Aβ clearance</li>
</ul>
<h3>Biomarker</h3>
<ul>
<li>CSF Aβ42 decreases before symptoms</li>
<li>Amyloid PET positive years before dementia</li>
<li>Anti-amyloid drugs reduce plaques</li>
</ul>
<h3>Recent Validation</h3>
<ul>
<li>Lecanemab and donanemab show clinical efficacy</li>
<li>Slowing of cognitive decline when plaques cleared</li>
</ul>
<h2>Evidence Challenging</h2>
<h3>Timing Issues</h3>
<ul>
<li>Plaques precede symptoms by decades</li>
<li>Tau pathology correlates better with symptoms</li>
<li>Cognitively normal individuals with plaques exist</li>
</ul>
<h3>Failed Therapies (Historical)</h3>
<ul>
<li>Many anti-amyloid drugs failed (solanezumab, aducanumab controversy)</li>
<li>Plaque removal without clinical benefit in some trials</li>
</ul>
<h3>Modified Hypotheses</h3>
<ul>
<li>Oligomer-centric (not plaques)</li>
<li>Upstream triggers (inflammation, metabolism)</li>
<li>Aβ as downstream consequence</li>
<li>Network-centric models</li>
</ul>
<!-- NEO4J_CONTENT_START -->
<h2>Relationships</h2>
<h3>Related</h3>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/autophagy-lysosomal-pathway/" class="internal-link">Autophagy-Lysosomal_Pathway</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">-Secretase_Modulators</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Cerebral_Amyloid_Angiopathy</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/neuron-derived-exosome-biomarkers/" class="internal-link">Neuron-Derived_Exosome_Biomarkers</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Synaptic_Dysfunction</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/gfap/" class="internal-link">GFAP</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau_Phosphorylation</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/examination/amyloid-pet-imaging/" class="internal-link">Amyloid_PET_Imaging</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/intervention/sleep-optimization/" class="internal-link">Sleep_Optimization</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/condition/mild-cognitive-impairment/" class="internal-link">Mild_Cognitive_Impairment</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/plasma-amyloid-beta-ratio/" class="internal-link">Plasma_Amyloid-Beta_Ratio</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Alzheimers_Disease</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Amyloid-Beta_4240_Ratio</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">BACE1_Inhibitors</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:48:39.716975'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Donanemab</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Lecanemab</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Synaptic_Dysfunction</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Cerebral_Amyloid_Angiopathy</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">-Secretase_Modulators</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/neuroinflammation/" class="internal-link">Neuroinflammation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">BACE1_Inhibitors</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau_Phosphorylation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a class="internal-link is-unresolved" href="/404">Aging</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/intervention/sleep-optimization/" class="internal-link">Sleep_Optimization</a> (intervention)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:48.863953'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/examination/amyloid-pet-imaging/" class="internal-link">Amyloid_PET_Imaging</a> (examination)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:44.235597'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/biomarker/plasma-amyloid-beta-ratio/" class="internal-link">Plasma_Amyloid-Beta_Ratio</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:15.960616'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/biomarker/neuron-derived-exosome-biomarkers/" class="internal-link">Neuron-Derived_Exosome_Biomarkers</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:15.353378'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/biomarker/gfap/" class="internal-link">GFAP</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:12.668732'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau_Phosphorylation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:12.950584'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/pathway/neuroinflammation/" class="internal-link">Neuroinflammation</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:12.428247'
source: obsidian
</code></pre>
<ul>
<li>← <a href="/garden/dev_admin/pathway/autophagy-lysosomal-pathway/" class="internal-link">Autophagy-Lysosomal_Pathway</a> (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/protein/app/" class="internal-link">APP</a> (protein)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/amyloid-beta-4240-ratio/" class="internal-link">Amyloid-Beta_4240_Ratio</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimers_Disease</a> (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/examination/amyloid-pet-imaging/" class="internal-link">Amyloid_PET_Imaging</a> (examination)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/protein/apoe/" class="internal-link">ApoE</a> (protein)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/gene/psen1/" class="internal-link">PSEN1</a> (gene)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ <a href="/garden/dev_admin/condition/mild-cognitive-impairment/" class="internal-link">Mild_Cognitive_Impairment</a> (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<!-- NEO4J_CONTENT_END -->
<h2>Relationships</h2>
<h3>Upstream Factors</h3>
<ul>
<li>→ <a href="/garden/dev_admin/protein/app/" class="internal-link">APP</a> (gene) - <em>Aβ precursor</em></li>
<li>→ <a href="/garden/dev_admin/protein/apoe/" class="internal-link">APOE</a> (gene) - <em>Clearance modulator</em></li>
<li>→ <a href="/garden/dev_admin/gene/psen1/" class="internal-link">PSEN1</a> (gene) - <em>γ-secretase component</em></li>
<li>← <a href="/garden/dev_admin/process/aging/" class="internal-link">Aging</a> (process) - <em>Primary risk factor</em></li>
</ul>
<h3>Downstream Effects</h3>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/tau-phosphorylation/" class="internal-link">Tau Phosphorylation</a> (pathway) - <em>Triggered by Aβ</em></li>
<li>→ <a href="/garden/dev_admin/pathway/neuroinflammation/" class="internal-link">Neuroinflammation</a> (pathway) - <em>Microglial activation</em></li>
<li>→ <a href="/garden/dev_admin/pathway/synaptic-dysfunction/" class="internal-link">Synaptic Dysfunction</a> (pathway) - <em>LTP inhibition</em></li>
</ul>
<h3>Diseases</h3>
<ul>
<li>→ <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimer's Disease</a> (condition) - <em>Central hypothesis</em></li>
<li>→ <a href="/garden/dev_admin/condition/cerebral-amyloid-angiopathy/" class="internal-link">Cerebral Amyloid Angiopathy</a> (condition) - <em>Vascular amyloid</em></li>
<li>→ <a href="/garden/dev_admin/condition/mild-cognitive-impairment/" class="internal-link">Mild Cognitive Impairment</a> (condition) - <em>Prodromal stage</em></li>
</ul>
<h3>Biomarkers</h3>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/amyloid-beta-4240-ratio/" class="internal-link">Amyloid-Beta 42/40 Ratio</a> (biomarker) - <em>CSF/plasma</em></li>
<li>← <a href="/garden/dev_admin/examination/amyloid-pet-imaging/" class="internal-link">Amyloid PET Imaging</a> (examination) - <em>Plaque visualization</em></li>
</ul>
<h3>Therapeutic Targets</h3>
<ul>
<li>← <a href="/garden/dev_admin/drug/lecanemab/" class="internal-link">Lecanemab</a> (drug) - <em>Anti-Aβ antibody; FDA approved</em></li>
<li>← <a href="/garden/dev_admin/drug/donanemab/" class="internal-link">Donanemab</a> (drug) - <em>Anti-Aβ antibody</em></li>
<li>← <a href="/garden/dev_admin/drug/bace1-inhibitors/" class="internal-link">BACE1 Inhibitors</a> (drug) - <em>Reduce production</em></li>
<li>← <a href="/garden/dev_admin/drug/secretase-modulators/" class="internal-link">γ-Secretase Modulators</a> (drug) - <em>Shift Aβ42/40 ratio</em></li>
</ul>
<h2>Therapeutic Strategies</h2>
<h3>Production Inhibition</h3>
<ul>
<li>BACE1 inhibitors (discontinued due to toxicity)</li>
<li>γ-secretase modulators</li>
</ul>
<h3>Clearance Enhancement</h3>
<ul>
<li>Anti-Aβ immunotherapy (successful)</li>
<li>APOE-targeted approaches</li>
<li>Proteolytic degradation enhancement</li>
</ul>
<h3>Aggregation Prevention</h3>
<ul>
<li>Small molecule aggregation inhibitors</li>
<li>Oligomer-selective antibodies</li>
</ul>
<h3>Combination Approaches</h3>
<ul>
<li>Anti-amyloid + anti-tau</li>
<li>Disease-modifying + symptomatic</li>
</ul>
<h2>Current Status (2025)</h2>
<h3>FDA-Approved Therapies</h3>
<ul>
<li><strong>Lecanemab (Leqembi)</strong>: Protofibrils; ~27% slowing</li>
<li><strong>Donanemab (Kisunla)</strong>: N-terminal Aβ; ~35% slowing</li>
</ul>
<h3>Implications</h3>
<ul>
<li>Validates amyloid as therapeutic target</li>
<li>Earlier intervention likely more effective</li>
<li>Combination with tau therapies anticipated</li>
</ul>
<h2>References</h2>
<ol>
<li><strong>Original Hypothesis</strong>: Hardy, J., et al. (1992). &quot;The amyloid cascade hypothesis.&quot; <em>Science</em>.</li>
<li><strong>Oligomer Hypothesis</strong>: Selkoe, D.J. (2002). &quot;Alzheimer's disease is a synaptic failure.&quot; <em>Science</em>.</li>
<li><strong>Lecanemab Trial</strong>: van Dyck, C.H., et al. (2023). &quot;Lecanemab in early Alzheimer's disease.&quot; <em>NEJM</em>.</li>
</ol>

{% endraw %}